It was a 20 bagger between 2020 and 2021 when the science was proven by consecutive successful clinical trials alongside the mere whiff of approval and commercialisation. Now, with the benefit of hindsight, these two ultimate goals are actually a real prospect. Bring on the next fluctuation, for this most certainly isn't a stock that fits any sort of bell curve, and thank goodness for that!
DNA testing has a concerning suboptimal ability to detect early stage cancer, which is the whole point of population screening. Furthermore, it mostly still involves poo, is expensive, and does not utilise readily available lab machines and skill sets. It's already 'out there' but hasn't yet replaced the FIT and FOBT tests due to these very serious limitations. It is however suited to disease monitoring for those already diagnosed, so does have it's place.
I'm pretty sure that those who sold out, or didn't buy in, will look back and kick themselves for focussing on petty accusations of insider trading instead of looking at the bigger picture of a brilliant and proven technology, a determined Board, and soon, money in the bank to fuel renewed progress.
Expand
